A review on wearable and contactless sensing for COVID-19 with policy challenges

The COVID-19 pandemic has affected more than 100 million people worldwide, with around 500,000 cases reported daily. This has led to the overwhelming of healthcare systems even in developed countries such as the US, UK, etc. Remote monitoring of COVID-19 patients with nonserious symptoms can help reduce the burden on healthcare facilities and make them available for high risk groups and the seriously affected. The pandemic has accelerated the demand for the remote patient monitoring (RPM) technologies, and the market is expected to reach 2.14 billion in 2027 from the value of 786.4 million in 2019. In RPM programs, there are two types of sensors that can be used: wearable and contactless. The former, which is currently more widely used, is not only more obtrusive and uncomfortable, but can also lead to cross-infection through patient contact. These two types of technologies are discussed and compared for each vital sign. In the respiratory system, the vital signs are the respiratory rate (RR) and oxygen saturation (SpO2), while for the latter, they are the heart rate/rhythm and the blood pressure (BP). Then, the discussion is broadened to policy level changes needed to expedite the use of such technologies for remote patient monitoring (RPM) in the world. Around 80% of countries’ RPM programs are either informal or in a pilot phase, and thus lack policies and an established regulatory framework to implement their programs. The various policies needed to initiate, deliver, and reimburse RPM programs during emergency situations and outbreaks are /discussed. Finally, technologies such as contactless systems, robotics, and Internet-of-things(IoT) that will revolutionize healthcare in the future by reducing the interaction between physicians and patients and cross-infection are discussed